Literature DB >> 12963701

Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?

Richard L Schilsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12963701     DOI： 10.1200/JCO.2003.07.942

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?

Authors:  Elizabeth A Richey; E Alison Lyons; Jonathan R Nebeker; Veena Shankaran; June M McKoy; Thanh Ha Luu; Narissa Nonzee; Steven Trifilio; Oliver Sartor; Al B Benson; Kenneth R Carson; Beatrice J Edwards; Douglas Gilchrist-Scott; Timothy M Kuzel; Dennis W Raisch; Martin S Tallman; Dennis P West; Steven Hirschfeld; Antonio J Grillo-Lopez; Charles L Bennett
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

2.  Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness.

Authors:  Melanie McPhail; Emma Weiss; Tania Bubela
Journal:  Front Med (Lausanne)       Date:  2022-02-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.